Nektar Therapeutics Announces Completion of Target Enrollment in REZOLVE-AA Phase 2b Clinical Trial of Rezpegaldesleukin in Patients with Severe-to-Very Severe Alopecia Areata

Core Insights - Nektar Therapeutics has completed target enrollment in its Phase 2b study of rezpegaldesleukin for severe-to-very-severe alopecia areata, achieving an enrollment of 84 patients [1][2] Company Overview - Nektar Therapeutics is a clinical-stage biotechnology company focused on developing treatments for autoimmune and chronic inflammatory diseases, with rezpegaldesleukin as its lead product candidate [9] - Rezpegaldesleukin is a first-in-class regulatory T cell stimulator being evaluated in two Phase 2b clinical trials, one for alopecia areata and another for atopic dermatitis [9] Study Details - The REZOLVE-AA study enrolled patients with severe-to-very-severe alopecia areata who have not previously received JAK inhibitors or other biologics, with randomization across two dose regimens of rezpegaldesleukin or placebo [2][4] - The primary efficacy endpoint is the mean percent change in the Severity of Alopecia Tool (SALT) score at the end of a 36-week induction period, with secondary endpoints including the proportion of participants achieving a 50% reduction in SALT score [2][4] Clinical Context - Alopecia areata is an autoimmune disease affecting hair follicles, with a lifetime incidence of 2% in both men and women, impacting approximately 6.7 million people in the U.S. and 160 million worldwide [7][8] - Current therapies for alopecia areata have high relapse rates and there is a significant unmet medical need for more effective treatments [8] Mechanism of Action - Rezpegaldesleukin targets the interleukin-2 receptor complex to stimulate the proliferation of regulatory T cells, potentially restoring immune system balance in autoimmune conditions [5][6]